glp-1 nine in one Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24 Oral Small-Molecule GLP-1 Receptor Agonists:

Therapeutic potential of GLP-1RAs in other rheumatologic and dermatologic disorders The potential effects of GLP-1 RAs on PsD can be more clearly understood by examining how these drugs interact with the molecular and cytokine pathways common to PsD and other rheumatologic and dermatologic conditions, including rheumatoid arthritis (RA), osteoporosis (OP), osteoarthritis (OA), psoriasis (PsO), and hidradenitis suppurativa (HS) (Table 4)

Therefore, hospital-based information pharmacists are worth promoting and developing

Animal studies paint a mixed picture

Consider holding GLP-1 agonists on the day of the procedure or a week prior to the procedure, depending on the dosing schedule of the individual GLP-1 agonists

Future directions Future research directions for the use of GLP-1R agonists in the treatment of pain and headache disorders should focus on conducting human trials to evaluate their efficacy and safety, particularly in individuals with comorbid obesity [60]